NCT01778686View on ClinicalTrials.gov

Evaluation of [11C]Cimbi-36 as an Agonist PET Radioligand for Imaging of 5-HT2A Receptors

NACompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Healthy
Interventions
DRUG

Citalopram and Pindolol

"Citalopram: selective serotonin reuptake inhibitor~Pindolol: non-selective beta blocker and 5-HT1A receptor antagonist"

OTHER

Placebo

On the second PET scanning day, subjects received a protein drink as well as a 50 ml saline infusion over 1 hour starting 30 min before PET scanning.

DIETARY_SUPPLEMENT

Acute tryptophan depletion

Trial Locations (1)

2100

Neurobiology Research Unit, Rigshospitalet, Copenhagen

All Listed Sponsors
lead

Gitte Moos Knudsen

OTHER

NCT01778686 - Evaluation of [11C]Cimbi-36 as an Agonist PET Radioligand for Imaging of 5-HT2A Receptors | Biotech Hunter | Biotech Hunter